MenaQ7
 Zyflamed
 Immunity
 Gabamox
 
 
        Activities                    
   
  Activites > News
 
 
16 January 2012
Article on the Effect of MenaQ7 published by the American Journal of Kidney Disease
In a press release on December 10, 2009 Nattopharma announced the first use of MenaQ7, the natural vitamin K2, as an intervention in a placebo controlled clinical trial on dialysis patients. The aim of the study was to assess the effects of natural vitamin K2 on vascular health parameters in a patient group that has a very high degree of risk for cardiovascular disease.

A peer reviewed article entitled "Effect of Vitamin K2 Supplementation on Functional Vitamin K Deficiency in Hemodialysis Patients: A Randomized Trial" by Ralf Westenfeld, Thilo Krueger, Georg Schlieper, Ellen C.M. Cranenburg, Elke J. Magdeleyns, Stephan Heidenreich, Stefan Holzmann, Cees Vermeer, Willi Jahnen-Dechent, Markus Ketteler, Jürgen Floege and Leon J. Schurgers is now e-published by the American Journal of Kidney Disease

The authors of the article state that:

The study confirms that most hemodialysis patients have a functional vitamin K deficiency. More importantly, it is the first study showing that inactive MGP levels can be decreased markedly by daily vitamin K2 supplementation. Our study provides the rationale for intervention trials aimed at decreasing vascular calcification in hemodialysis patients by vitamin K supplementation

For more information, please press here
 
  Omicron Pharmaceuticals | 2017 | All rights reserved